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Developmental reprogramming techniques have been used to generate induced
pluripotent stem (iPS) cells from both normal and malignant cells. The derivation of
iPS cells from cancer has the potential to provide a unique scientific tool to overcome
challenges associated with the establishment of cell lines from primary patient samples
and a readily expandable source of cells that may be used to model the initial disease.
In the current study we developmentally reprogrammed a metastatic Ewing sarcoma
(EWS) cell line to a meta-stable embryonic stem (ES)-like state sharing molecular and
phenotypic features with previously established ES and iPS cell lines. EWS-iPS cells
exhibited a pronounced drug resistant phenotype despite persistent expression of the
oncogenic EWS-FLI1 fusion transcript. This included resistance to compounds that
specifically target downstream effector pathways of EWS-FLI1, such as MAPK/ERK and
PI3K/AKT, which play an important role in EWS pathogenesis. EWS-iPS cells displayed
tumor initiation abilities in vivo and formed tumors exhibiting characteristic Ewing
histopathology. In parallel, EWS-iPS cells re-differentiated in vitro recovered sensitivity
to molecularly targeted chemotherapeutic agents, which reiterated pathophysiological
features of the cells fromwhich they were derived. These data suggest that EWS-iPS cells
may provide an expandable disease model that could be used to investigate processes
modulating oncogenesis, metastasis, and chemotherapeutic resistance in EWS.
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Introduction
Ewing sarcoma (EWS) is the second most common type of primary bone malignancy in
children and adolescents (Ries and SEER Program (National Cancer Institute (US)), 1999;
Burchill, 2003). EWS is a highly invasive, undifferentiated tumor of unknown histogenic ori-
gin whose molecular underpinnings, in approximately 85% of tumors, are associated with the
expression of the EWS-FLI1 fusion product generated by the t(11;22)(q24;q12) chromosomal
translocation (Arvand and Denny, 2001). The EWS-FLI1 transcript encodes a rogue transcrip-
tion factor that deregulates the expression of various target genes, which is suggested to pro-
mote the activation of multiple pro-oncogenic signals (Lessnick and Ladanyi, 2012). Although
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EWS typically responds to initial combination chemotherapy
treatment, approximately one-third of patients will suffer from
recurrent, metastatic disease despite aggressive multimodal ther-
apeutic approaches (Grier et al., 2003; Miser et al., 2007). Accord-
ingly, the derivation of novel molecularly targeted therapies
is paramount in improving patient outcomes and will require
a greater understanding of the molecular mechanisms driving
EWS oncogenesis, metastasis, and drug resistance. Although our
principal understanding of the disease has advanced through-
out the years with investigation of various EWS disease models,
such approaches have presented with a number of limitations. As
the cell of origin in EWS is unknown, a number of studies have
depended on heterologous cell types as a model system for EWS
to investigate the oncogenic fusion protein (May et al., 1993a,b,
1997); however, such model systems were later shown to lack the
expression patterns of patient-derived tumors (Braunreiter et al.,
2006; Hancock and Lessnick, 2008). Further, while the develop-
ment of human model systems expressing EWS-FLI1 in various
cell types more closely resemble gene expression alterations in
EWS (Lessnick et al., 2002; Rorie et al., 2004; Hu-Lieskovan et al.,
2005; Riggi et al., 2008), they do not accurately reproduce multi-
ple aspects of the original disease. From a research standpoint, the
identification of novel oncogenic mechanisms and therapeutic
targets would ideally involve the use of patient-derived tumors,
but this is complicated by inherent difficulties in establishing and
maintaining primary tumor cell cultures. For instance, various
primary EWS (Vormoor et al., 2001) as well as other established
tissue sarcoma cell lines (Mills et al., 2009) simply fail to grow or
exhibit slow growth kinetics in vitro which hamper their utility
for scientific or clinical investigations. Moreover, those exhibit-
ing slow growth phenotypes are likely more susceptible to the
accrual of additional mutations and phenotypic alterations due to
extended in vitro expansion times. Efforts to circumvent inherent
issues associated with in vitro culture have involved the propaga-
tion of human primary tumor cells in murine xenograft models;
however, these too have been met with various challenges regard-
ing phenotypic preservation and patient tumor model accuracy.
As is the case with a majority of human solid tumor xenograft
models, the growth characteristics and tumor progression of
xenotransplanted EWS cells (Scotlandi et al., 1998) unsuccess-
fully recapitulates the growth characteristics observed in patients
and exhibits little histopathological resemblance to that of the
original tumor from which the cells were derived (Mills et al.,
2009). This highlights a current unmet need to identify additional
ex vivo tumor cell propagation strategies that are focused toward
the preservation of the molecular and phenotypic characteristics
pathognomonic of the original diagnosed tumor.
Developmental reprogramming techniques have been used to
generate iPS (induced pluripotent stem) cells from both normal
(Takahashi et al., 2007; Park et al., 2008) and malignant cells
(Utikal et al., 2009; Carette et al., 2010; Miyoshi et al., 2010;
Kumano et al., 2012); a process that is achieved through the
cellular transduction of a defined set of pluripotency transcrip-
tion factors. This technology affords not only a unique scientific
tool that may be utilized in the development of patient-specific
stem cell-based regenerative therapies, but also in the establish-
ment of disease models to investigate pathogenesis. Kumano
et al. reported the successful derivation of iPS cells from primary
chronic myelogenous leukemia (CML) patient samples (Kumano
et al., 2012). These CML-derived iPS cells maintained expres-
sion of the oncogenic BCR-ABL fusion transcript (encoding a
constitutively active, mutant tyrosine kinase), yet exhibited resis-
tance to the receptor tyrosine kinase inhibitor, imatinib. Intrigu-
ingly, CML-iPS cells were capable of effectively re-differentiating
into hematopoietic cells that recuperated sensitivity to imatinib,
which reiterated pathophysiological features of the initial disease
(Kumano et al., 2012). Such studies demonstrated that develop-
mental reprogramming techniques may be employed to expand
primary hematologic malignancies difficult to propagate in vitro.
Further, Kumano and colleagues revealed that these iPS cells
could be expanded in vitro without restriction and redifferen-
tiated into CML hematopoietic cells that phenocopy the initial
disease. This strategy affords the means to preserve the primary
tumor phenotype and the ability to obtain a large quantity of
viable cells that would be required for epigenomic, transcrip-
tomic, proteomic, and importantly, large scale drug screen stud-
ies. Thus, we postulated that this technology may be extended
to aid the investigation of other malignancies, including that of
EWS, proven difficult to establish, maintain, and expand in cul-
ture. Therefore, once reprogrammed, EWS-iPS cells may provide
an easily expandable and unlimited source of viable EWS cells
that may be routinely obtained through their re-differentiation
in vitro.
Given that some malignancies are refractory to iPS cell gen-
eration, here we sought to initially investigate whether or not
a EWS cell line was susceptible to reprogramming and if re-
differentiation of such cells could reproduce pathophysiological
features of cells from which they were derived. In this study
we developmentally reprogrammed EWS cells to a meta-stable
ES-like state sharing a multitude of molecular features with pre-
viously established ES and iPS cell lines. EWS-iPS cells showed
sustained expression of the EWS-FLI1 fusion transcript, yet were
resistant to small molecule inhibitors of oncogenic pathways
downstream of EWS-FLI1. Re-differentiated EWS-iPS main-
tained tumor formation competency in vivo giving rise to tumors
with characteristic Ewing histopathology and demonstrated
recovery of drug sensitivity upon re-differentiation in vitro, thus
reiterating the pathophysiological features of the initial cell line.
Materials and Methods
Cell Culture
HEK293T cells were maintained in DMEM containing 10%
FBS, 1% L-glutamine, and 1% penicillin/streptomycin. CHLA-10
cells (May et al., 2013) were grown in IMDM containing 20%
FBS, 0.2% L-glutamine, and 1X ITS Premix (BD Biosciences).
HEK293T and CHLA-10 cells were passaged every 4–5 days using
trypsin or Puck’s saline A solution, respectively. iPS cell lines
were grown on mitomycin C-treated MEF feeder layers as previ-
ously described (Hotta et al., 2009) and maintained in ES media
consisting of Knockout DMEM (Invitrogen) supplemented with
20% Knockout Serum Replacement (Invitrogen), 1X Nonessen-
tial amino acids (Invitrogen), 1X Glutamax (Invitrogen), 1X
Antibiotic/Antimycotic (Invitrogen), 0.1mM 2-mercaptoethanol
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(Invitrogen), 10 ng/ml human bFGF (Invitrogen), and 1µg/ml
puromycin. ES media was replaced daily and iPS cells were trans-
ferred to newly derived MEF feeder layers every 5 days follow-
ing collagenase IV dissociation (1mg/ml for 20min at 37◦C), as
previously described Hotta et al., 2009.
iPS Cell Line Derivation
Cellular reprogramming was performed using a variation of
a previously described method (Yu et al., 2009). CHLA-10 or
HEK293T cells were induced to pluripotency via nucleofection-
mediated delivery of an oriP/EBNA1-based episomal vector
(pEP4-EO2S-EN2K: Addgene 20925, Yu et al., 2009) contain-
ing OCT4, SOX2, NANOG, and KLF4 together with a reporter
plasmid [PL-Sin-EOS-S(4+)-EiP: Addgene 21314 (Hotta et al.,
2009)]. The reporter construct contained eGFP and puromycin
selectable markers under the control of a Sox2-responsive ETn
promoter. Sample preparation and Nucleofection was performed
using the Neon
TM
Transfection system (Invitrogen) as directed
by the manufacturer’s instructions. Briefly, two million CHLA-
10 or HEK293T cells were electroporated with 5µg of reporter
with either 5µg of reprogramming or empty vector using a sin-
gle 40ms pulse of 1100 volts. Electroporated cells were plated
on MEF feeder layers maintained in DMEM complete media
lacking antibiotics. Four days following electroporation, DMEM
complete media was replaced with ES complete media. Thirteen
days after nucleofection, cells were transferred to fresh ES media
containing 1µg/ml puromycin. Approximately 1 month follow-
ing transduction of the reprogramming factors, cultures were
screened for the emergence of iPS cell colonies.
Immunocytochemistry
iPS cell colonies grown were fixed in 4% paraformaldehyde,
permeabilized with 0.25% Triton X-100, and blocked in 5%
goat serum in PBST. Cells were incubated with primary anti-
body overnight at 4◦C, washed with PBST, and incubated with
DyLight 650 (ab98371 or ab102464; Abcam) conjugated sec-
ondary antibody. Rat monoclonal to SSEA3 (ab16286), mouse
monoclonal to SSEA4 (ab16287), and mouse monoclonal to
TRA-1-60 (ab16288) antibodies were supplied by Abcam, in
addition to rat IgM (ab35768) and mouse IgM (ab18401) isotype
controls. iPS cells were counter stained with 0.5µg/ml DAPI and
rinsed with PBS prior to fluorescence microscopic imaging.
PCR Analysis of OriP/EBNA1-Based Episomal
Vector
Episomal plasmid DNA was purified from iPS cells as performed
by Ziegler et al. (2004) and assessed for the presence of vector
specific OCT4, SOX2, NANOG, and KLF4 transgenic sequences
via polymerase chain reaction with specified primers as formerly
described by Yu et al. (2009). Purified pEP4 backbone/empty
vector and pEP4-EO2S-EN2K reprogramming plasmid served as
negative and positive controls in PCR reactions, respectively.
Semi-Quantitative RT-PCR Analysis of
Pluripotency Genes
Total RNA was isolated and prepared using TRIzol R© reagent
(Invitrogen), as per manufacturer instructions. 500 ng of total
RNA was reverse transcribed using the Bio-Rad iScript
TM
cDNA Synthesis Kit (Bio-Rad) with Oligo(dT) primers. Semi-
quantitative PCR was performed to assess the RNA expression
of total, endogenous and recombinant pluripotency genes. The
primers used for detection of total NANOG, OCT4, SOX2, and
KLF4 are as follows: Nanogt primers, 5
′-GATTTGTGGGCC
TGAAGAAA-3′ and 5′-AAGTGGGTTGTTTGCCTTTG-3′;
Oct4t primers, 5
′-CTCACCCTGGGGGTTCTATT-3′ and 5′-
AGCTTCCTCCACCCACTTCT-3′; Sox2t primers, 5
′-CAAG
AC GCTCATGAAGAAGG-3′ and 5′-GTTCATGTGCGCGTAA
CTGT-3′; Klf4t primers, 5
′-ACCCACACAGGTGAGAAACC-3′
and 5′-ATGTGTAAGGCGAGGTGGTC-3′. The human actin
gene was detected as an endogenous control with the following
primers: Actin (forward): 5′-GACCTGGCTGGCCGGGACCT-
3′, Actin (reverse): 5′-GGCCATCTCTTGCTCGAAGT-3′. PCR
was performed using recombinant, Taq DNA Polymerase (Invit-
rogen) according to the manufacturer’s protocol for 35 cycles
with an annealing temperature of 62◦C. Amplified products were
resolved on 1X TBE agarose gels and visualized by ethidium
bromide staining.
Alkaline Phosphatase Staining
iPS cell colonies were cultured on MEF feeder layers for 5 days.
Cells were then analyzed for AP activity using an Alkaline Phos-
phatase Detection Kit (SCR004; Millipore, Billerica, MA) accord-
ing to the manufacturer’s protocol.
In Vitro Embryoid Body Formation
To induce embryoid body formation, iPS cells were dissociated
fromMEF feeder layers with collagenase IV, transferred to plastic
Petri dishes containing ES medium without bFGF, and cultured
in suspension for 6 days.
In Vivo Teratoma and Tumor Formation Assays
iPS cell colonies were dissociated (1mg/ml collagenase IV) from
MEF feeder layers, washed with DMEM base media, and sus-
pended in DMEM containing 10% FBS to an approximate final
concentration of 2 × 107 cells/ml. Resultant colonies, consisting
of approximately 1–2million cells (100µL), were subcutaneously
injected into 5–7 week old NOG (NOD/Shi-scid/IL-2Rγnull)
mice. Injected mice were monitored for 6–12 weeks and tumor
dimensions measured with precision calipers. Tumors approach-
ing 0.75 cm3 in size were excised, rinsed with PBS, and fixed in
10% formalin. Hematoxylin/Eosin staining was performed by the
Department of Molecular and Comparative Pathobiology at the
Johns Hopkins School of Medicine. For tumor formation assays
EWS-iPS cells were dissociated from feeder layers, mechanically
separated into individual cell suspensions to promote differenti-
ation, and suspended in IMDM base media containing 20% FBS,
0.2% L-Glut, 0.1% ITS prior to subcutaneous injection (approxi-
mately 1million cells). Subsequently, mice weremonitored for 6–
12 weeks and tumor dimensions measured. Tumor growth rates
(
1Log(tumor volume(mm3)
1 Time (days)
) were determined and reported using lin-
ear regression analysis of semi-log plots {Log [tumor volume
(mm3)] vs. Time (days)}. Again, tumors reaching 0.75 cm3 in
size were excised, rinsed with PBS, and fixed in 10% formalin.
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Hematoxylin/Eosin staining was performed by theMolecular and
Comparative Pathobiology core.
Chemo-Sensitivity Assays
Approximately 5000 CHLA-10 parent or EWS-iPS cells were
plated per well of 0.1% porcine gelatin coated 96-well tissue-
culture plates in triplicate. The following day, parental and
EWS-iPS cell medium was replaced with 100µL of 10µM YK-
4-279, 0.1µMmithramycin, 300µMU-0126, 30µM rapamycin,
100µM LY294002 or untreated DMSO vehicle in ES media and
incubated for 48 h. During drug exposure, all cultures were incu-
bated in iPS cell base media containing 10 ng/ml human bFGF to
control for potential variations in drug resistance due to growth
factor signaling (Dini et al., 2002). Cell viability was subsequently
assessed using a Cell Titer 96 R© Aqueous One Solution Cell Pro-
liferation Assay (MTS Reagent; Promega) according to the man-
ufacturer’s instructions. Drug responses were determined for all
cell lines by comparing the amount of formazan product for-
mation in treated to untreated cells by measuring spectropho-
tometric absorbance at 490 nanometers. For chemo-sensitivity
assays utilizing in vitro differentiated cells, EWS-iPS were man-
ually dissociated into individual cell suspensions and plated in
Ewing complete media in the absence of bFGF for a period of
48 h prior to drug exposure.
DNA Methylation Profiling
Genomic DNA was extracted using the Wizard R© Genomic DNA
Purification Kit (Promega) and 300 ng bisulfite converted using
the methylSEQr
TM
Reagent Kit (Applied Biosystems) according
to each manufacturer’s protocol. Bisulfite converted DNA was
hybridized to an Infinium 450K Bead Chip (Illumina). The 450K
chip was processed and scanned by the Sydney Kimmel Compre-
hensive Cancer CenterMicroarray Core facility at the JohnsHop-
kins School of Medicine. 450K data was background subtracted
and filtered of null-signal probes in Genome Studio and subse-
quently exported to R version 2.15.1 × 64 bit (The R Project for
Statistical Computing). The level of methylation at each CpG site,
defined as the ratio of methylated allele to the sum of methylated
and unmethylated alleles, or β-value, ranges from 0.0 to 1.0 (com-
pletely unmethylated to completely methylated, respectively). β-
values were analyzedwithin R utilizing the Bioconductor (version
2.5) and Methylumi (version 2.2.0) statistical packages. Unsuper-
vised hierarchical clustering was used to examine methylation
status in an unbiased fashion, and clustering was performed, with
Euclidian distance and complete linkage using the heatmap.2
function in the gplots library.
Accession Numbers
Previously published 450K DNA Methylation array data from
25 ES, 29 iPS, 6 differentiated ES, 6 differentiated iPS cells, and
5 hydatidiform mole samples are available at the NCBI GEO
database under the accession series designation GSE31848.
EWS-FLI1 Gene Expression Analysis
Total RNA was isolated and prepared using TRIzol R© reagent
(Invitrogen) according to the manufacturer’s instruction. 500 ng
of total RNA was reverse transcribed using a Bio-Rad iScript
TM
cDNA Synthesis Kit (Bio-Rad, Hercules, CA) with random
primers. Quantitative PCR was performed with iQ
TM
SYBR R©
Green Supermix (Bio-Rad) in a Bio-Rad CFX96 Real-Time
Instrument. The primers used for the detection of the EWS-FLI1
fusion transcript included the following: EWS-FLI1 (forward):
5′-TCCTACAGCCAAGCTCCAAGTC-3′ and EWS-FLI1
(reverse): 5′-GAATTGCCACAGCTGGATCTGC-3′. The human
porphobilinogen deaminase (PBGD) gene was detected as an
internal control for normalization with the following primers:
PBGD (forward): 5′-GGAGCCATGTCTGGTAACGGCA-3′,
PBGD (reverse): 5′-GGTACCCACGCGAATCACTCTCA-3′).
PCR was performed with an initial denaturation at 95◦C for
3min, followed by 35 cycles of 30 s at 95◦C, 30 s at 55◦C, and 30 s
at 72◦C. Relative gene expression was calculated according to the
11CT method for quantitative real-time PCR.
Statistical Analysis
Statistical analyses were performed using the descriptive statis-
tics data analysis toolpak add-in available through the Microsoft
Office Excel program. Statistical significance (p-values) among
data sets was determined using a student’s two-tailed t-test.
Results
Developmental Reprogramming of the Metastatic
EWS Cell Line, CHLA-10
In the current study we sought to developmentally reprogram
an established metastatic EWS cell line sourced from a patient-
derived primitive neuroectodermal tumor (PNET), designated
CHLA-10 (May et al., 2013), via nucleofection-mediated deliv-
ery of an EBNA1-based 4 factor (OCT3/4, NANOG, SOX2, and
KLF4) episomal construct (Figure 1A). This particular cell line
was considered ideal for preliminary reprogramming studies due
to its uniform phenotype, relatively short doubling time (≈32 h),
and amenability to electroporation. Utilizing the aforementioned
strategy, putative reprogrammed CHLA-10 or EWS-iPS colonies
were generated. They exhibited classical iPS cell morphologi-
cal features and closely resembled HEK293T iPS cells gener-
ated by the same reprogramming strategy (Figure 1B). Putative
EWS-iPS cell colonies were distinguished from partially repro-
grammed cells by the presence of stem cell-specific antigens. Of
the suspected iPS cell clonal populations isolated, immunofluo-
rescence spectroscopy confirmed clones B and C to express Tra-
1-60, SSEA-3 and SSEA-4 stem cell markers (Figure 2A). Using
these clones, two EWS-iPS cell lines free of integrated transgenic
sequences were generated. OriP/EBNA-based episomal vectors
are gradually lost through mitosis during clonal expansion (Yu
et al., 2009; Chou et al., 2011). Consistent with these observations,
PCR analysis of the transgenic reprogramming factors demon-
strated the high passage EWS-iPS clone B (>25 passages) to have
lost and the low passage EWS-iPS clone C (<10 passages) to have
maintained the episomal plasmid (Figure 2B). Both clones exhib-
ited an increase in total expression levels (endogenous and trans-
genic sources) of characteristic embryonic stem cell transcripts
(OCT3/4, NANOG, SOX2, and KLF4), as evidenced by semi-
quantitative PCR (Figure 2C). In addition, alkaline phosphatase
(AP) activity was measured to evaluate the undifferentiated state
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 March 2015 | Volume 3 | Article 15
Moore et al. Reprogramming Ewing sarcoma
FIGURE 1 | Generation of iPS cells from the Ewing cell line,
CHLA-10. (A) Cell reprogramming schematic and timeline. (B) EWS-iPS
cell colonies (A–E) enriched for the expression of SOX2 via puromycin
selection are discernible by GFP fluorescence. Parent (HEK293T and
CHLA-10), as well as HEK293T iPS cell controls are shown (scale = 200
micron).
of EWS-iPS cells. Relative to the HEK293T iPS cell positive con-
trol line, both EWS-iPS clones B and C also expressed substantial
levels of AP (Figure 2D). However, high levels of AP activity
observed in the CHLA-10 parent strain precluded the utility of
this approach as a distinctive marker.
The differentiation potential of EWS-iPS cells was subse-
quently assessed by performing an embryoid body formation
assay. To induce embryoid body formation, bFGFwas withdrawn
from the media and both EWS-iPS cells (clones B and C) and
parental cells were grown in suspension on petri dishes for 6 days.
Like the HEK293T iPS cell control, both EWS-iPS cell clones (B
and C) displayed typical embryoid body features forming charac-
teristic spheroid aggregates with increasingly complex interiors,
indicative of cellular differentiation (Figure 2E). In contrast, this
was not observed with CHLA-10 parental cells cultured under the
same conditions where growth appeared unorganized.
Further, teratoma formation assays were performed to assess
the differentiation potential of the EWS-iPS cell lines (Figure 2F).
Tumors derived from EWS-iPS cell clone B exhibited a restricted
capacity to spontaneously differentiate into the three embryonic
germ lineages and predominately formed tissues of mesodermal
origin, i.e., adipose, bone, cartilage, and skeletal muscle. EWS-
iPS cell clone C exhibited a broader differentiation capacity and
gave rise to all three embryonic lineages (endoderm, ectoderm
and mesoderm), including cells of adipogenic and osteogenic lin-
eage, as well as glandular and neural tissues. The disparity in
differentiation capacity between these EWS-iPS cell lines demon-
strates the variable developmental states between clones and fur-
ther, may also reflect differences in iPS cell quality related to
passage number (Okada and Yoneda, 2011). Despite the high
developmental potential of both EWS-iPS cell lines, a moderate
fraction of undifferentiated cells were visible in both sets of ter-
atomas, indicating that these reprogrammed cells remain capa-
ble of contributing to poorly differentiated tumorigenic tissue
exhibiting characteristic EWS histology (see below for further
details).
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FIGURE 2 | EWS-iPS cell characterization. (A) Immunofluorescence
microscopic detection of stem cell specific antigens (SSEA3, SSEA4, and
TRA-1-60) in EWS-iPS clones. Brightfield, FITC, and DAPI nuclear stained
cells are presented. Mouse IgM and rat IgM negative controls are shown.
Scale = 200 micron. (B) PCR analysis of the EBNA1/oriP-based
transgenic reprogramming factors in EWS-iPS clone B and clone C cells
(right panel). Purified pEP4-EO2S-EN2K and empty pEP4 reprogramming
plasmid controls are shown (left panel). (C) RT-PCR analysis of total ES
cell-specific transcripts. Reverse transcriptase minus (-RT) control
reactions are shown. (D) Alkaline phosphatase staining of parent (left
column) and derived iPS cells (right column). (E) In vitro embryoid body
(EB) formation assays. CHLA-10 parent, EWS-iPS B and C, and control
HEK293T-iPS EBs. Scale = 200 micron. (F) Teratoma formation assays.
H&E sections of control CHLA-10 (top panel), EWS-iPS cell clone B
(middle panels), and EWS-iPS cell clone C (bottom panels) xenografts are
shown. Astericks (∗) denote undifferentiated Ewing cells and yellow
arrows denote myoblasts. Magnified images are depicted in yellow boxes.
Scale = 200 micron.
EWS-iPS Cells Share Methylation Patterns with
Other ES and iPS Cell Lines
An analysis of DNA methylation demonstrated comparable
methylation patterns among EWS-iPS and 2 iPS cell lines
obtained from the NCBI GEO database (Figure 3A). Further,
these methylation patterns were distinctly different from both
the CHLA-10 parent and TC32 Ewing cell lines grown as
spheroids or in monolayer. A more extensive comparison of
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FIGURE 3 | Comprehensive analysis of DNA methylation. (A,B)
Dendograms depicting unsupervised hierarchical clustering based on
differential methylation at 7687 differentially methylated CpGs. In the
accompanying heatmaps, green indicates a CpG methylation of less than
50% and red of more than 50%. Unsupervised hierarchical clustering based
on differential methylation at (C) promoter regions of endogenous ES
pluripotency genes and (D) stem cell specific DMRs. Heatmaps depict
background subtracted β-values. TSS and 5′UTR denote probes located at
transcriptional start sites and 5′untranslated regions, respectively.
Methylation values for comparative cell lines (25 ES, 6 differentiated ES, 29
iPS, 6 differentiated iPS, and 5 hydatidiform mole samples) were obtained
from the NCBI GEO database.
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DNA methylation (Figure 3B) with additional cell lines and
tissues revealed that EWS-iPS cells possessed methylation pat-
terns that more closely resembled those of lower passaged ES
and iPS cell lines and were distinct from the methylation pat-
terns of the more differentiated tissues (differentiated ES and
iPS cells, hydatidiform moles, the TC32 EWS cell line and the
CHLA-10 Ewing parent cell lines). Moreover, multiple CpG sites
spanning the promoter regions of some key endogenous ES
pluripotency genes (i.e., NANOG, POU5F1, and SOX2) exhib-
ited similar hypomethylated patterns among EWS-derived and
other iPS cells (Figure 3C). Previous work investigating iPS cell
methylation dynamics has aided in the identification of stem cell-
specific densely methylated regions (DMRs) that are subject to
significant expression alterations in human iPS cells (Nishino
et al., 2011). Consistent with these reports, we identified numer-
ous altered CpG sites in EWS-iPS cells (compared to parent
Ewing cell lines), spanning the promoter regions of several stem
cell specific DMRs, that demonstrated comparable methylation
patterns with previously established iPS cells (Figure 3D).
EWS-iPS Cells Maintain EWS-FLI1 Oncogene
Expression Yet Acquire Resistance to Targeted
Agents
In a previous study, iPS cells generated from CML patient-
derived tumors exhibited an acquired resistance to recep-
tor tyrosine kinase-targeted inhibition with imatinib despite
unremitting expression of the BCR-ABL oncogene (Kumano
et al., 2012). Such studies prompted us to investigate whether
cellular reprogramming influenced the methylation status of the
EWS promoter and/or altered corresponding oncogenic EWS-
FLI1 transcript expression levels in EWS-derived iPS cells. In
methylation array analyses EWS-iPS cells (clones B and C) exhib-
ited hypomethylation marks at numerous CpG sites spanning
the EWS promoter region and were comparable to that of the
parental CHLA-10, the TC32 Ewing cell line (grown as spheroids
or in monolayer), and two unrelated iPS cell lines (iPS201B7 and
HDF51IPS14) (Figure 4A). Consistent with the observed EWS
promoter hypomethylation, quantitative PCR revealed equiva-
lent expression of the EWS-FLI1 fusion transcript among EWS-
iPS and the CHLA-10 parental cells fromwhich they were derived
(Figure 4B), indicating that erasure of the epigenetic modifica-
tions during cellular reprogramming does not disrupt EWS-FLI1
oncogene expression in EWS-iPS cells. In light of this obser-
vation, we next determined if EWS-iPS and CHLA-10 parental
cells would exhibit equivalent sensitivities tomithramycin or YK-
4-279, both pharmacological agents that have been shown to
effectively target and inhibit EWS-FLI1 activity (Grohar et al.,
2011; Barber-Rotenberg et al., 2012). Cell lines were exposed to
mithramycin, YK-4-279, or DMSO vehicle for a period of 48 h
and MTS assays were subsequently performed to determine rela-
tive cell viabilities (Figure 4C). Interestingly, cell viability assays
demonstrated that EWS-iPS cells are largely resistant to YK-
4-279 and mithramycin relative to the CHLA-10 parental cell
line (Figure 4C). Based on such data it appears that EWS-iPS
cells have developed resistance to pharmacological EWS-FLI1
inhibitors in spite of persistent expression of the oncogenic fusion
FIGURE 4 | EWS-iPS cells demonstrate preservation of oncogene
expression and acquired resistance to EWS-FLI1 targeted agents. (A)
Dendograms depicting the methylation status of CpG sites spanning the EWS
promoter of CHLA-10 parent, TC32 Ewing (grown in monolayer or as
spheriods), EWS-iPS (clones B and C), and control iPS (iPS201B7_1312 and
HDF51IPS_592) cell lines. Green indicates a CpG methylation of less than
50% and red of more than 50%. TSS and 5′UTR denote probes located at
transcriptional start sites and 5′untranslated regions, respectively. (B)
EWS-FLI1 gene expression in CHLA-10 parent (n = 4) and EWS-iPS (n = 4)
(clones B and C) cells. Standard error of the mean is reported. p = 0.80 (iPS B
vs. CHLA-10) and p = 0.64 (iPS C vs. CHLA-10). (C) Drug sensitivity assays.
CHLA-10 parent (n = 6), iPS B (n = 3), or iPS C (n = 3) cell lines were exposed
to chemotherapeutic agents or DMSO vehicle (untreated) in iPS base media
containing 10 ng/ml human bFGF for a period of 48 h. Following treatment,
MTS assays were performed and relative cell viabilities determined (relative cell
viability = 490 nm absorbance treated/490 nm absorbance untreated).
Standard error of the mean is reported. ∗p < 0.0001 (iPS vs. CHLA-10).
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product. This suggests that epigenetic alterations imposed dur-
ing the reprogramming process provided the EWS cells drug
resistance.
EWS-iPS Cells Exhibit Tumor Initiating Properties
As the EWS-iPS cells appeared to have undergone significant
phenotypic alterations during the reprogramming process, we
sought to determine if these cells were competent to re-
differentiate into EWS-like cells from which they were derived.
In vitro differentiation was induced by plating individual
cell suspensions in IMDM media for 48 h. EWS-iPS cells
readily re-differentiated into cells that were morphologically
indistinguishable from the parental CHLA-10 cells (Figure 5A).
SOX2 expression was also shown to decrease upon in vitro
differentiation of EWS-iPS cells, as demonstrated by a reduction
in intensity of the SOX2-responsive green fluorescence reporter.
Contrary to differentiated iPS, EWS-iPS cell suspensions cultured
in ES medium displayed small-round-refractile morphology
with sustained expression of the SOX2-responsive GFP reporter
(Figure 5A). Next, to investigate the tumor initiation compe-
tency and engraftment potential of these cells we next assessed the
in vivo growth rates and latencies of tumors that developed fol-
lowing subcutaneous injection of EWS-iPS or CHLA-10 parental
cell lines into immune-compromised mice. Both parental and
EWS-iPS cells exhibited comparable growth rates and tumor
latencies (Figure 5B). Importantly, EWS-iPS cells readily formed
undifferentiated tumor cells exhibiting the small-blue-round-cell
morphology that is characteristic of EWS (Figure 5C). Thus,
EWS-iPS cells exhibited comparable tumor initiating properties
with similar growth kinetics to that of the CHLA-10 parental
FIGURE 5 | EWS-iPS cells exhibit tumor initiating properties. (A)
EWS-iPS cells differentiate into Ewing cells that morphologically resemble
CHLA-10 parental cell lines in vitro. EWS-iPS (clones B and C) were
dissociated into individual cell suspensions (middle panels) and
differentiated by plating in Ewing media [IMDM, 20% FBS, 0.2% L-Glut,
0.1% ITS] for a period of 48 h (bottom panels). Red boxes denote
magnified fields. Brightfield or SOX2-dependent GFP marker channels are
shown (scale = 200 micron). (B) In vivo differentiated EWS-iPS (n = 5)
and parental (n = 9) cell lines possess comparable in vivo growth rates
(p = 0.28; iPS vs. CHLA-10) and tumor latencies (p = 0.41; iPS vs.
CHLA-10). Standard error of the mean is reported. (C) H&E stained
sections of control CHLA-10 (left panel), EWS-iPS B (middle panel), and
EWS-iPS C (right panel) tumor xenografts are shown. Astericks (∗) denote
blood vessels. Scale = 200 micron.
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cells, were able to re-differentiate into EWS-like cells in vitro,
and readily formed small-blue-round-cell tumors, characteristic
of Ewing histopathology in vivo.
Re-Differentiated EWS-iPS Cells Recover
Sensitivity to Agents Targeting Pathways
Downstream of EWS-FLI1
Ewing cells characteristically form poorly differentiated tumors
that lack distinguishing markers identifying mature tissue types,
thus we additionally utilized in vitro chemotherapeutic sensitivity
to agents targeting downstream effector pathways of EWS-FLI1
as a proxy for EWS differentiation of Ewing-derived iPS cells.
Given that both theMAPK/ERK and PI3K/AKT/mTOR signaling
cascades serve as major modulators of the oncogenic phenotype
in both EWS and EWS-FLI1 expressing cancer cell lines (Silvany
et al., 2000; Zenali et al., 2009), we chose U-0126, rapamycin,
and LY294002 pharmacological agents (targeted inhibitors of
ERK1/2, mTOR, and PI3K, respectively) for investigation in
subsequent chemo-sensitivity studies. CHLA-10 parental cells
exhibited significant sensitivity to the aforementioned molec-
ularly targeted agents (Figure 6A). In contrast, EWS-iPS cells
(clones B and C) were remarkably resistant to inhibitors target-
ing either the MAPK/ERK or PI3K/AKT pathways, suggesting
a potential loss of dependency upon the activity of these pro-
oncogenic signaling cascades downstream of EWS-FLI1 in repro-
grammed cells. Further, we investigated whether re-differentiated
EWS-iPS cells would recover sensitivity to other targeted agents.
As shown in Figure 6B, in vitro differentiated iPS cells exhibited
recuperated sensitivity to rapamycin and LY294002, inhibitors
targeting mTOR and PI3K, respectively; an effect that was more
pronounced in EWS-iPS clone B compared to clone C. In an
analogous fashion, both differentiated iPS cell clones showed a
similar degree of drug response recovery to the ERK inhibitor, U-
0126; however the magnitude of reduction in cell viability of the
iPS cells was less severe vis-à-vis CHLA-10 parental (Figure 6B).
Hence, while undifferentiated EWS-iPS cells were resistant, re-
differentiated EWS-iPS cells appeared to recuperate some sen-
sitivity to inhibitors of putative downstream EWS-FLI1 effector
pathways, similar to the original CHLA-10 cell line.
Discussion
While cancer cell nuclei have been suggested to not be amenable
to the reprogramming process (Hochedlinger et al., 2004), multi-
ple groups have generated putative iPS cells from various types of
malignancies (Carette et al., 2010; Miyoshi et al., 2010; Kumano
et al., 2012); however, reprogramming efficiencies were reported
to be low. In a synonymous manner, the derivation of iPS from
EWS cells via the introduction of a 4-factor (OCT4, NANOG,
SOX2, and KLF4) episomal construct yielded reduced repro-
gramming rates with an approximate efficiency of 0.0001%. Our
EWS-iPS cells displayed characteristic iPS cell-like morphology,
expressed ES cell surface markers, and exhibited DNA methyla-
tion patterns comparable to other ES and iPS cell lines. While
hierarchical cluster analysis of our EWS-iPS cells demonstrated
similar patterns of global methylation to other ES and iPS cell
lines, the degree of promoter hypomethylation of several stem
FIGURE 6 | Re-differentiated EWS-iPS cells recover sensitivity to
chemotherapeutic agents targeting oncogenic pathways downstream
of EWS-FLI1. CHLA-10 parent (n = 6) and (A) iPS (clones B and C; n = 3) or
(B) differentiated iPS (iPS diff. clones B and C; n = 3) were exposed to
chemotherapeutic agents or DMSO vehicle (untreated) in iPS cell base media
containing 10 ng/ml human bFGF for a period of 48 h. Following treatment,
MTS assays were performed and relative cell viabilities determined (relative cell
viability = 490 nm absorbance treated/490 nm absorbance untreated).
Standard error of the mean is reported. ∗p < 0.005 (iPS vs. CHLA-10).
cell-specific DMRs and some endogenous pluripotency genes was
not as pronounced in our EWS-iPS cells, thus suggesting that
the EWS-derived iPS cells may have been only partially repro-
grammed. This appeared to be the case in a recent study which
attempted to reprogram a EWS cell line via employing a her-
pesvirus saimiri-based (HSV) 3 factor (OCT4, NANOG, and
LIN28) vector; these cells, termed “induced multipotent cancer
cells (iPCs),” yielded only a partially reprogrammed phenotype
capable of differentiation toward the ectodermal lineage (Brown
et al., 2013). Contrary to this report, our EWS-derived iPS cell
clones (specifically B and C) exhibited capacity to differenti-
ate into a number of embryonic tissues. Both clones demon-
strated proclivity to differentiate into mesodermal tissues, and
clone C exhibited potential to form additional tissues of both
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endodermal and ectodermal origin (although less frequently than
that of mesoderm)—suggesting achievement of a true pluripo-
tent state. The disparity in differentiation capacity between these
clones may reflect the acquisition of differing epigenetic states
as a result of the inherent stochastic nature of the reprogram-
ming process. However, despite the fact that the reprogrammed
EWS cell-derived clones exhibit many of the prototypical iPS/ES
cell markers and phenotypic features, they fail to fully reca-
pitulate the developmental potential of other well established
iPS cell lines generated from non-malignant tissues (Takahashi
et al., 2007). Whether this is a consequence of deficiencies in
the reprogramming method employed in their derivation or
oncogene-mediated blockade of the proper coordinated epige-
netic alterations required for successful reprogramming is cur-
rently unknown. However, maintenance of specific epigenetic
marks, or rather maintaining some “epigenetic memory” of the
original EWS cell line, could prove advantageous for the purpose
of accurately modeling a particular disease following successful
re-differentiation.
Indubitably, numerous preclinical models have aided in
improving our understanding of the molecular basis of EWS.
However, the elucidation of novel molecular mechanisms driv-
ing oncogenesis and metastasis, as well as the identification of
new effective therapies for EWS has been hindered by inherent
limitations in existing tumor cell models. These include stud-
ies utilizing established cell lines that have been extensively pas-
saged in vitro, as well as those employing the transplantation of
primary tumor cells into tumor xenografts models (Mills et al.,
2009). Both models present with inherent challenges that may
obscure study results and conclusions. For example, some estab-
lished sarcoma cell lines have been passaged for more than a
decade which has been documented to influence both muta-
tion rates and genetic stability (Sherr and DePinho, 2000). Fur-
ther, immune compromised xenograft mouse models do not
harbor an environment that accurately recapitulates the native
in vivo sarcoma milieu. This is due to differing graft-host stro-
mal interactions and the absence of a functional immune system
(Pelleitier and Montplaisir, 1975) which have tremendous con-
sequences on microenvironment interactions and tumor orga-
nizational architecture. Issues such as these may help to explain
why numerous promising EWS therapeutic agents identified in
preclinical investigations have been slow to progress to clinical
development [i.e., targeted inhibitors of EWS-FLI1 activity: YK-
4-279 (Erkizan et al., 2009; Barber-Rotenberg et al., 2012) and
mithramycin (Grohar et al., 2011)] or unsuccessfully reproduce
anticipated salubrious effects in early phase clinical trials (i.e.,
IGF1R blocking antibodies: R1507 (Pappo et al., 2014), cixu-
tumumab (Malempati et al., 2012), and figitumumab (Juergens
et al., 2011). Based on the results of this study, EWS-iPS cells
may constitute a novel platform to bypass the aforementioned
difficulties associated with the establishment and expansion of
primary cell lines from patient tumors. This may also afford
the ability to expand primary cells that fail to grow under stan-
dard in vitro conditions—forgoing the need for xenotransplan-
tation in in vivo models. Following reprogramming, EWS-iPS
cells can be expanded limitlessly and routinely re-differentiated
into characteristic Ewing cells for high throughput drug screens
and/or other analyses requiring large quantities of viable cells.
EWS appears to exhibit a clinical profile whose underlying
biology is consistent with the cancer stem cell model. In this
model, disease relapse is attributed to the survival and expansion
of a subpopulation of cancer stem cells (CSCs) exhibiting a cyto-
toxic drug resistant phenotype. Prospective isolation of CSCs has
previously been reported in EWS where high ALDH expressing,
chemotherapy-resistant stem-like subpopulations were isolated
from related cell lines and human xenografts (Awad et al., 2010).
These EWS CSCs expressed putative pluripotency transcripts
(i.e., OCT4 and NANOG), exhibited tumor initiating activity
in vivo, and possessed a chemotherapy-resistant phenotype. In
this report, EWS CSCs appeared to share a number of phenotypic
properties with EWS-iPS cells, although EWS CSCs maintained
sensitivity to the pharmacological EWS-FLI1 inhibitor, YK-4-
279, implicating sustained maintenance of EWS-FLI1 oncogene
addiction or rather a dependency on EWS-FLI1 signaling. Unlike
EWS CSCs (Awad et al., 2010), EWS-iPS cells acquired resistance
to agents targeting EWS-FLI1, i.e., mithramycin and YK-4-279.
This suggests that epigenetic modifications during the repro-
gramming process or activation of specific pathways required
for iPS cell maintenance may supersede downstream EWS-FLI1-
mediated pathways. Given that there exists subpopulations of
EWS CSCs that exhibit heightened expression of pluripotency
associated transcripts it is tempting to speculate that there may
exist a portion of cells exhibiting a similar phenotype to that
of EWS-iPS cells. Losing the requirement for EWS-FLI1 onco-
gene signaling could explain, in part, the acquisition of resis-
tance to IGF1R inhibitors in EWS patients, a major downstream
effector pathway of EWS-FLI1 and significant contributor to
the oncogenic phenotype in EWS. The expression of the EWS-
FLI1 fusion gene in EWS induces post-transcriptional derepres-
sion of IGF pathway components (Prieur et al., 2004; McKinsey
et al., 2011) which consequently enhances MAPK/ERK as well
as PI3K/AKT/mTOR signaling (Silvany et al., 2000; Zenali et al.,
2009). Analogous to what was observed with agents that target
EWS-FLI1 activity, EWS-iPS cells appeared to be largely refrac-
tory to small molecule inhibitors targeting putative downstream
effector, signaling pathways of EWS-FLI1, i.e., ERK1/2, mTOR,
and PI3K. As both ERK1/2 and AKT phosphorylation have been
suggested to play important roles in the maintenance of iPS and
ES cell lines (Brill et al., 2009; Wang et al., 2009) via an inter-
play with pluripotency transcriptional network, we postulate that
the signaling for iPS cell maintenance likely compensates for
direct inhibition of EWS-FLI1 and/or inhibition of its down-
stream effector pathways; a phenomenon that could hold true
and, in part, underlie an additional mode of chemotherapeutic
resistance in a minor subpopulation of EWS cells. Thus, given
the high mortality rate and the possible cancer stem cell involve-
ment in metastasis and tumor recurrence (Awad et al., 2010),
undifferentiated EWS-iPS cells themselves may also provide a
valuable tool to investigate EWS tumor development and modes
of drug resistance via identifying the epigenetic modifications
and molecular pathway alterations contributing to their drug
resistance—current avenues of research that we are pursuing.
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